Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

Summary

Tissue Dynamics and Galmed Pharmaceuticals announced a collaboration to develop a human-centered cardiac fibrosis platform using vascularized, sensor-embedded cardiac organoid models to advance Aramchol-based therapeutics for post-MI remodeling and HFpEF.